External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience AAN 2025
Roche and Genentech at

AAN 2025

April 05 - April 09
California, USA
aan.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Apr 8 / Roche and Genentech
Ocrelizumab Subcutaneous Administration: Further Characterization of the Benefit-Risk Profile From the OCARINA II Study and Patient Preferences
Updated efficacy and safety data, and new patient-reported preference data are presented from the OCARINA II study.
Neuroscience Multiple Sclerosis AAN-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 8 / Roche and Genentech
Fenebrutinib maintains low disease activity in relapsing multiple sclerosis: results from the FENopta trial open-label extension
This analysis assessed the efficacy, safety and exploratory biomarkers, such as immunoglobulins and B cells, after fenebrutinib treatment in people with RMS enrolled int he FENopta open-label extension through Week 48.
Neuroscience Multiple Sclerosis AAN-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 7 / Roche and Genentech
Placental and Breastmilk Transfer of Ocrelizumab from Women with Multiple Sclerosis to Infants and the Potential Impact on B-Cell Levels: Primary Analysis of the Prospective, Multicenter, Open-Label, Phase IV Studies MINORE and SOPRANINO
MINORE is a prospective Phase IV, open-label study measuring placental transfer of ocrelizumab and potential impact on newborn B-cell levels, with detailed maternal and infant clinical outcomes, humoral immunity, safety and serum biomarkers. SOPRANINO is the first prospective study measuring pharmacodynamic and pharmacokinetic parameters of ocrelizumab in breastmilk and potential effects on infant humoral response to vaccines, safety, growth and development.
Neuroscience Multiple Sclerosis AAN-2025
08:36 PM
Duration 12mins San Diego Convention Center | 30C-E
Imaging and Fluid Biomarkers of Disability Progression During Two Years of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People With Multiple Sclerosis (MS) in CHIMES
Amezcua, Lilyana; Monson, Nancy L.; Williams, Mitzi J.; Reder, Anthony T.; Wu, Gregory F.; Vartanian, Timothy; Pei, Jinglan; Harp, Christopher; Clayton, David; Abioye, Ibraheem; Bernitsas, Evanthia
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:15 PM
Duration 10mins Ballroom 20
Placental and Breastmilk Transfer of Ocrelizumab from Women with Multiple Sclerosis to Infants and the Potential Impact on B-Cell Levels: Primary Analysis of the Prospective, Multicenter, Open-Label, Phase IV Studies MINORE and SOPRANINO
Bove, Riley; Oreja-Guevara, Celia; Vukusic, Sandra; Shah, Anna; Graham, Edith L.; McElrath, Thomas; Pietrasanta, Carlo; Dobson, Ruth; Maillart, Elisabeth; Jacobs, Dina; Kletzl, Heidemarie; Kazlauskaite, Agne; Zecevic, Dusanka; Raposo, Catarina; Craveiro, Licinio; Lin, Chien-Ju; Pasquarelli, Noemi; Hellwig, Kerstin
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:45 PM
Duration 60mins California, USA
Reduced cerebrospinal fluid biomarkers (neurofilament light chain, B cells, T cells) and improved clinical/imaging assessments of disease activity are sustained after 5 years of ocrelizumab treatment: long-term extension results from OBOE
Gelfand, Jeffrey; Bar-Or, Amit; Agbim, Chinaza; von Büdingen, H. Christian; Cameron, Briana; Casavant, Ellen; Herman, Ann E.; Jia, Xiaoming; Ramesh, Akshaya; Winger, Ryan; Jiang, Jenny; Harp, Chris; Cross, Anne
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:00 PM
Duration 60mins California, USA
Ocrelizumab Subcutaneous Administration: Further Characterization of the Benefit-Risk Profile From the OCARINA II Study and Patient Preferences
Newsome, Scott D; Goldstick, Lawrence; Selmaj, Krzysztof; Krzystanek, Ewa; Zecevic, Dusanka; Figueiredo, Catarina; Clinch, Susanne; Giacobino, Caroline; Azmi, Jay; Centonze, Diego
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins California, USA
Fenebrutinib maintains low disease activity in relapsing multiple sclerosis: results from the FENopta trial open-label extension
Bar-Or, Amit; Oh, Jiwon; Dufek, Michal; Budincevic, Hrvoje; Habek, Mario; Caunt, Maresa; Sierzega, Malgorzata; Clayton, David; Chen, Ying-Fang; Ratchford, John N.; Goodyear, Alexandra; Drulovic, Jelena
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.